AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.
Professor Uta Griesenbach gave a presentation entitled ‘Gene Therapy for Rare Respiratory Diseases’ on Tuesday, March 19, 2024 5:10 PM to 5:30 PM in Gene Therapy Track 7.
Our InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest.
We have shown single dose efficacy, long-term durability of effect (critically retaining an ability to re-dose if required), combined with the convenience of administration, transforming the current standard of care of frequent IV bolus injections, or providing therapeutic solutions for diseases that currently do not exist.
We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF).
For for more information or to arrange a meeting please email us at [email protected]
